Fourth quarter revenues of $2.62 billion, up 14.5% from 2023 Fourth quarter reported diluted earnings per share ("EPS") of $1.95, up 14.7% from 2023; and adjusted diluted EPS of $2.23, up 3.7% from 2023 Full year revenues of $9.87 billion, up 6.7% from 2023 Full year reported diluted EPS of $7.69, up 2.7% from 2023; and adjusted diluted EPS of $8.93, up 2.5% from 2023 Full year 2025 reported diluted EPS expected to be between $8.34 and $8.59; and adjusted diluted EPS expected to be between $9.55 and $9.80S ...

Physicians and patients to benefit from access to Quest's industry-leading test menu and broad health plan relationships in OhioSECAUCUS, N.J. and CLEVELAND, Jan. 27, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of select assets of University Hospitals, one of the nation's leading nonprofit health systems and academic medical centers. Financial terms were not disclosed.With the ...

Quest Diagnostics (DGX) is set to release its fourth-quarter 2024 results on Jan. 30 before the market opens.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The renowned diagnostics provider posted adjusted earnings per share (EPS) of $2.30 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 1.77%. The company topped earnings estimates in each of the trailing four quarters, the average surprise being 3.41%.DGX’s Q4 EstimatesFor the fourth quarter of 2024, the ...

Executive Appointment - Adrienne L Brott has been appointed as Senior Vice President and Chief Quality and Regulatory Affairs Officer at Quest Diagnostics [1][2] - The appointment took effect in December 2024 [3] Role and Responsibilities - Ms Brott will lead the company's quality and regulatory strategy to enhance quality adherence and control as well as compliance with US and global regulations and industry standards for laboratory diagnostic information services [3] - She reports directly to Jim Davis, Chairman, CEO and President, and is a member of the company's Executive Leadership Team [3] Professional Background - Prior to joining Quest Diagnostics, Ms Brott served as senior vice president, quality and regulatory for the acute care therapies division of Getinge [4] - She held various leadership roles at Becton Dickinson (BD), including senior vice president, quality management--interventional segment, quality systems and regions, where she led all aspects of quality across 28 manufacturing sites worldwide and led a multi-year program to simplify and harmonize 120 quality management systems [4] - She has experience in quality systems and post-market quality and regulatory compliance and quality operations and end-to-end integrated supply chain operations for medical devices and other areas for Johnson & Johnson and Abbott Laboratories [4] Industry Involvement - Ms Brott is a co-chair of the Advancing Quality Excellence Collaborative Community (AQEcc) Steering Committee of the Medical Device Innovation Consortium (MDIC), an initiative shared by medical device stakeholders, including the FDA, to enhance medical device quality and patient safety [5] Educational Background - Ms Brott holds a Master of Business Administration (MBA) degree from the Lake Forest Graduate School of Management [6] - She earned a bachelor's degree with a double major in biology and environmental studies from Lake Forest College in Illinois [6] Company Overview - Quest Diagnostics is a leading provider of diagnostic information services, serving one in three adult Americans and half the physicians and hospitals in the United States annually [7] - The company has more than 50,000 employees and operates one of the world's largest databases of de-identifiable clinical lab results [7]

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Quest Diagnostics (DGX) , which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, could be a great candidate to consider.When looking at the last two reports, this medical laboratory operator has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 1.75%, on average, in the last two quarte ...

Quest Diagnostics Inc. (DGX) has availed a personalized, one-on-one health coaching service on questhealth.com, through its subsidiary, Pack Health. The holistic programs focus on several key areas, including general health, weight management, chronic kidney disease, type 2 diabetes, or high cholesterol.For a more customised experience, individuals can pair their Quest lab work with their health coaching to put their diagnostic insights into action.Predicting DGX Stock Movement Following the NewsAfter the a ...

New service takes the guesswork out of achieving one's health goals by empowering individuals to pair Quest lab results with personalized coachingSECAUCUS, N.J,, Dec. 3, 2024 /PRNewswire/ -- Personalized, one-on-one health coaching is now available for purchase on questhealth.com. Made available by Pack Health®, a Quest Diagnostics (NYSE: DGX) company that provides evidence-based patient engagement services, questhealth.com's Health Coaching pairs individuals with board-certified health advisers who provide ...

A month has gone by since the last earnings report for Quest Diagnostics (DGX) . Shares have added about 2.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Quest Diagnostics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Quest Diagnostics Tops Q3 Earnings and Rev ...

Quest Diagnostics (DGX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of ...

Core Business and Growth Drivers - Quest Diagnostics' Advanced Diagnostics portfolio is driving growth, particularly in brain health with AD-Detect blood-based Alzheimer's disease testing and in women's health with prenatal and hereditary genetic testing [3] - The company is seeing robust demand for testing in genital tract infections, including several STIs [3] - In the cardio-metabolic health space, there is growing interest in biomarkers for early detection of cardiovascular and metabolic diseases, and the acquisition of Haystack Oncology has positioned the company in the high-growth area of ctDNA solid-tumor MRD testing [4] - Physician Lab Services experienced strong growth in Q3 2024 due to new customer wins, expanded business from Advanced Diagnostics utilization, and acquisitions [5] - Hospital Lab Services is growing above historical levels, supported by strong demand for reference testing [6] - The questhealthcom platform reported 40% growth in total revenues, driven by consumer-initiated testing and demand for expanded access to basic healthcare [6] Financial Performance and Market Position - Quest Diagnostics has a market capitalization of $1788 million and an earnings yield of 555%, outperforming the industry's yield of 345% [2] - The company's earnings surpassed estimates in the trailing four quarters, with an average surprise of 492% [2] - The Zacks Consensus Estimate for 2024 EPS is $889, with revenue expected to grow 58% to $979 billion [11] - The stock has increased 208% over the past year, compared to the industry's 294% growth and the S&P 500's 337% growth [1] Operational Excellence and Cost Management - Quest Diagnostics is strategically deploying automation and AI to improve quality, service, efficiency, and workforce experience [7] - The company's Invigorate program has consistently delivered 3% annual cost savings and productivity enhancements, helping to mitigate inflationary pressures [7] - The company completed the build-out of full end-to-end automation for core routine tests at its Lenexa, KS laboratory, making it the third fully automated lab in its national network [8] - Quest Diagnostics is piloting automated specimen accessioning in its Clifton lab to increase productivity and improve quality [8] Challenges and Risks - The company's long-term debt stood at $565 billion at the end of Q3 2024, with cash and cash equivalents at only $764 million [9] - COVID-19 testing revenues have declined significantly, with a nearly 85% drop last year and an expected $175 million decline in 2024, partially offsetting base business growth [10] Industry Comparison - Haemonetics (HAE) has an earnings yield of 502%, surpassing the industry's 118%, and its shares have risen 203% against the industry's 73% decline over the past year [12] - Boston Scientific (BSX) has a long-term estimated earnings growth rate of 138%, with shares rallying 643% compared to the industry's 265% gain [13] - Penumbra (PEN) has an estimated earnings growth rate of 335% for 2024, compared to the industry's 159%, with shares rising 99% against the industry's 234% growth [14]